Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 23;18(1):32.
doi: 10.1186/s12865-017-0213-0.

IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report

Xin-Yao Wu  1 , Yu-Feng Yin  1 , Jia-Lin Teng  1 , Li-Wei Zhang  2 , Cheng-de Yang  3
Affiliations
Case Reports

IgMk paraprotein from gammopathy patient can bind to cardiolipin and interfere with coagulation assay: a case report

Xin-Yao Wu et al. BMC Immunol. .

Abstract

Background: The monoclonal gammopathies are a group of plasma-cell proliferative disorders characterized by the secretion of monoclonal immunoglobulin (M protein or paraprotein). Some rare cases have revealed the specific affinity of paraprotein as autoantibody. Here we report a patient with monoclonal gammopathy of undetermined significance (MGUS) accompanied by a remarkable increase of anticardiolipin antibody (aCL) and an extensively decreased coagulation factor activity, however, without any clinical signs of antiphospholipid syndrome (APS) and bleeding.

Results: Our further investigation indicated that IgMκ paraprotein of this patient possessed an antibody activity against phospholipids so as to bind to cardiolipin and interfere with coagulation assay in vitro.

Conclusions: This case might be indicative that an abnormality of coagulation tests, disturbed by IgMκ paraprotein, does not predict a risk of bleeding in this patient.

Keywords: Antibody; Coagulation; Monoclonal Gammopathy; Paraprotein; Phospholipid.

PubMed Disclaimer

References

    1. International Myeloma Working G Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757. doi: 10.1046/j.1365-2141.2003.04355.x. - DOI - PubMed
    1. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev. 2003;194:112–139. doi: 10.1034/j.1600-065X.2003.00056.x. - DOI - PubMed
    1. Caers J, Vekemans M-C, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, et al. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Ann Med. 2013;45(5–6):413–422. doi: 10.3109/07853890.2013.801562. - DOI - PubMed
    1. Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12(11):854–856. doi: 10.1191/0961203303lu463cr. - DOI - PubMed
    1. Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15(10):1490–1494. doi: 10.1093/annonc/mdh385. - DOI - PubMed

Publication types

LinkOut - more resources